Where U.S. Medicines Are Made and How Trump’s Tariffs Could Affect Them

President Trump’s planned pharmaceutical tariffs threaten to hit many of the most common and well-known drugs that Americans take.

News
Novo Nordisk, Ozempic Drugmaker, Sees Stock Plunge 20% After Profit Warning

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.

News
Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugs

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer.

News
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

News
Wegovy Can Treat a Dangerous Liver Disease, Study Finds

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

News
What to Know About Eli Lilly’s Daily Pill for Weight Loss

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.

News
Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.

News
Weight Loss Drug Will Be Offered for $499 a Month for Some Patients

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.

News
Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

News
Medicare to Negotiate Lower Prices for Weight-Loss Drugs

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

News